Dr. Gottlieb said transactions like the CVS Health-Aetna or Cigna-Express Scripts deals could make it easier for drugmakers to limit access to cheaper generic drugs that compete with their own brand-name products.
“We don’t have direct purview over it, but we do have something to say about it, and we’re going to be speaking to the PBMs about it,” Dr. Gottlieb said at the conference, according to Reuters.
The FDA head also shared the agency’s plans to create about a dozen policies to encourage more competition between expensive biotech medicines and their biosimilar versions.
More articles on supply chain:
Study: 40% of providers have canceled surgeries over supply shortages
10 immensely overinflated hospital costs
California leads way on drug pricing transparency with other states poised to follow: 6 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
